P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS

P766: CLINICAL OUTCOMES IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES RECEIVING HYPOMETHYLATING AGENTS: A LARGE POPULATION-BASED ANALYSIS

Bibliographic Details
Main Authors:	A. M. Zeidan, E. S. Mearns, C. Ng, A. Shah, N. Lamarre, A. Yellow-Duke, N. Alrawashdh, B. Yang, W. Cheng, C. N. Bui, A. Svensson
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845948.33476.47

Similar Items

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
by: A. Zeidan, et al.
Published: (2022-06-01)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
by: Rami S. Komrokji, et al.
Published: (2022-11-01)

Meta-analysis on hypomethylating agents in myelodysplastic syndromes
by: Christine Herbst, et al.
Published: (2010-02-01)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
by: Sangmin Lee, et al.
Published: (2022-08-01)

P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
by: K. Chien, et al.
Published: (2022-06-01)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
by: Nathan Radakovich, et al.
Published: (2022-10-01)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
by: Vincent G. Sorrentino, et al.
Published: (2021-07-01)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
by: Juliane Grimm, et al.
Published: (2022-08-01)

Integrating advanced analytical methods to assess epigenetic marks affecting response to hypomethylating agents in higher risk myelodysplastic syndrome
by: Theodoros Nikolopoulos, et al.
Published: (2025-02-01)

P723: CLINICAL AND MOLECULAR ASSOCIATIONS WITH OUTCOMES IN HIGHER RISK MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS PLUS VENETOCLAX
by: Alexandre Bazinet, et al.
Published: (2023-08-01)

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients
by: Ludan Zhang, et al.
Published: (2024-05-01)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
by: Xiaoyan Hu, et al.
Published: (2023-02-01)

Evaluation of induction chemotherapies after hypomethylating agent failure in myelodysplastic syndromes and acute myeloid leukemia
by: Brian Ball, et al.
Published: (2018-08-01)

From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes
by: Caner Saygin
Published: (2023-02-01)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
by: Samuel Urrutia, et al.
Published: (2023-08-01)

The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
by: Aziz Nazha, et al.
Published: (2016-06-01)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
by: Ahmad Ghorab, et al.
Published: (2022-06-01)

S171: HIGHER MDMX EXPRESSION WAS ASSOCIATED WITH HYPOMETHYLATING AGENT RESISTANCE AND WORSE SURVIVAL IN MYELODYSPLASTIC SYNDROME PATIENTS, INFERRING IT A POTENTIAL THERAPEUTIC TARGET
by: Yu-Hung Wang, et al.
Published: (2023-08-01)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
by: Xiaozhen Liu, et al.
Published: (2023-08-01)

Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations.
by: Santini, V, et al.
Published: (2014)

Predictors of Febrile Neutropenia and Role of Levofloxacin Prophylaxis in Acute Myeloid Leukemia And High-Risk Myelodysplastic Syndrome Patients Treated With Hypomethylating Agents
by: A. Fiorentini, et al.
Published: (2020-09-01)

P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE
by: K. Kim, et al.
Published: (2022-06-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

P730: EVOLUTION OF IPSS-M RISK CATEGORIES IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FROM DIAGNOSIS TO HYPOMETHYLATING AGENT FAILURE
by: Kelly Chien, et al.
Published: (2023-08-01)

ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling
by: Guangjie Zhao, et al.
Published: (2022-09-01)

RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME
by: Raoul Tibes
Published: (2013-08-01)

PB1821: COMBINATION OF BCL-2 INHIBITOR, HYPOMETHYLATION AGENTS AND LOW-DOSE CYTARABINE AS A SALVAGE THERAPY FOR ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROMES
by: X.-N. Gao, et al.
Published: (2022-06-01)

P745: MULTI-CENTER PHASE IB TRIAL OF THE HISTONE DEACTYLASE INHIBITOR ENTINOSTAT + PEMBROLIZUMAB IN MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA REFRACTORY TO HYPOMETHYLATING AGENTS
by: Jan Bewersdorf, et al.
Published: (2023-08-01)

Genome-wide analysis toward the epigenetic aetiology of myelodysplastic syndrome disease progression and pharmacoepigenomic basis of hypomethylating agents drug treatment response
by: Stavroula Siamoglou, et al.
Published: (2023-04-01)

Post‐remission cytopenia management in patients with AML treated with venetoclax in combination with hypomethylating agents: Pre‐ versus post‐VIALE‐A real‐world experience from a predominantly US community setting
by: Pankit Vachhani, et al.
Published: (2023-09-01)

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome
by: De‐hong Wu, et al.
Published: (2020-01-01)

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
by: Talha Badar, et al.
Published: (2024-02-01)

Commentary: Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: A systematic review and meta-analysis
by: David Beauvais, et al.
Published: (2022-10-01)

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
by: Laura Vilorio-Marqués, et al.
Published: (2022-09-01)

Phenotypic and functional changes of NK cells in patients with myelodysplastic syndrome and acute myeloid leukemia treated with hypomethylating drugs
by: D. I. Zhigarev, et al.
Published: (2021-05-01)

Elevated TWIST1 expression in myelodysplastic syndromes/acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine
by: Hongjiao Li, et al.
Published: (2020-01-01)

The wolf of hypomethylating agent failure: what comes next?
by: Anne Sophie Kubasch, et al.
Published: (2019-08-01)

The key role of microRNA-766 in the cancer development
by: Jitendra Gupta, et al.
Published: (2023-05-01)

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia
by: Catherine C. Coombs, et al.
Published: (2016-11-01)

P764: RESPONSE AND SURVIVAL OUTCOMES WITH HYPOMETHYLATING AGENTS IN AN ARGENTINEAN COHORT OF 113 PATIENTS WITH CHRONIC MYELOMONOCITIC LEUKEMIA
by: J. Gonzalez, et al.
Published: (2022-06-01)